Benlysta Articles
Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity
4 April 2013
Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR
25 October 2012
Barriers to overcome in lupus drug development
22 July 2012
New briefs: GSK extends HGS tender offer; J&J plans for $600 million charge; FDA delays prophylactic Truvada
10 June 2012
UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin
27 April 2012
Thought leaders indicate Benlysta has advantages over market leader CellCept for Lupus
26 April 2012
Human Genome Sciences’ Benlysta sales disappoint
11 January 2012
Benlysta gaining bigger US market share
13 December 2011
Benlysta to drive lupus drug market to $2.1 billion in 2020
26 October 2011
UK NICE negative on Sanofi’s Jevtana and GSK’s Benlysta but positive on ALK-Abello’s Pharmalgen
30 September 2011
Remicade, Humira and Enbrel made up 40% of the immunomodulators market in 2010; report
23 August 2011
Benlysta heading in right direction, but uptake slower than originally expected, says BioTrends
7 August 2011
EU approval for GlaxoSmithKline and Human Genome’s Benlysta; Slowing Advair sales in USA
15 July 2011
Slew of good news from EMA advisory panel for Benlysta, Fampyra, Vibativ, Victrelis, Xgeva and Yervoy
23 May 2011
Rheumatologists’ uptake of Benlysta will not lead to decline in patient share for immunosuppressant/cytotoxics or for Rituxan through 2013
24 February 2011
GlaxoSmithKline and Human Genome see shares rise after getting US FDA advisory panel backing for lupus drug Benlysta
17 November 2010
GlaxoSmithKline and Human Genome fall as US FDA questions lupus drug candidate Benlysta
15 November 2010
GlaxoSmithKline and partner Human Genome get US FDA priority review for Benlysta; GSK ups stake in Chinese vaccines JV
20 August 2010
Human Genome Sciences lures Celgene exec to help in European launch of Benlysta; Sanofi-Aventis announces executive moves in Asia
15 August 2010
GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019
10 August 2010
US rheumatologists express significant interest in Benlysta, the first novel drug for lupus in decades
16 June 2010
Good and bad news for Human Genome Sciences, as it files Benlysta BLA but mapatumumab disappoints in Ph II
11 June 2010
Merck Serono resubmits cladribine as a potential MS therapy in USA; GSK/HGS file Benlysta in Europe
8 June 2010
Human Genome/GlaxoSmithKline lupus drug Benlysta disappoints in Ph III; Updates on Seattle Genetics and Ligand milestones
21 April 2010
Showing 1-38 of 38 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
